Assetmark, Inc Insmed Inc Transaction History

Assetmark, Inc

$36.4 Billion
Q4 2024

A detailed history of Assetmark, Inc transactions in Insmed Inc stock. As of the latest transaction made, Assetmark, Inc holds 26,344 shares of INSM stock, worth $2.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,344

Previous 26,053 1.12%

Holding current value

$2.07 Million

Previous $1.9 Million 4.37%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$66.29 - $76.63 $19,290 - $22,299	291 Added 1.12%	26,344 $1.82 Million
Q3 2024 Nov 01, 2024	BUY	$62.0 - $79.01 $184,450 - $235,054	2,975 Added 12.89%	26,053 $1.9 Million
Q2 2024 Aug 13, 2024	BUY	$22.0 - $69.71 $388,454 - $1.23 Million	17,657 Added 325.71%	23,078 $1.55 Million
Q1 2024 May 06, 2024	SELL	$25.72 - $29.94 $12,705 - $14,790	-494 Reduced 8.35%	5,421 $147,000
Q4 2023 Feb 09, 2024	BUY	$23.42 - $31.74 $26,136 - $35,421	1,116 Added 23.25%	5,915 $183,000
Q3 2023 Oct 27, 2023	BUY	$19.86 - $26.93 $9,195 - $12,468	463 Added 10.68%	4,799 $121,000
Q2 2023 Aug 11, 2023	BUY	$16.44 - $21.1 $11,655 - $14,959	709 Added 19.55%	4,336 $91,000
Q1 2023 May 05, 2023	BUY	$16.26 - $21.73 $17,739 - $23,707	1,091 Added 43.02%	3,627 $61,000
Q4 2022 Feb 10, 2023	BUY	$16.98 - $23.15 $22,583 - $30,789	1,330 Added 110.28%	2,536 $50,000
Q3 2022 Nov 01, 2022	BUY	$20.88 - $28.21 $6,994 - $9,450	335 Added 38.46%	1,206 $26,000
Q2 2022 Aug 03, 2022	BUY	$17.07 - $25.71 $8,278 - $12,469	485 Added 125.65%	871 $17,000
Q1 2022 May 13, 2022	BUY	$20.42 - $28.13 $7,882 - $10,858	386 New	386 $9,000

Others Institutions Holding INSM

# of Institutions

484

Shares Held

187M

Call Options Held

2.15M

Put Options Held

3.22M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.7B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account